Advertisement
Mayo Clinic Proceedings Home

Differential Effect of β-Blockers According to Heart Rate in Acute Myocardial Infarction Without Heart Failure or Left Ventricular Systolic Dysfunction: A Cohort Study

      Abstract

      Objective

      To evaluate the effect of β-blockers according to heart rate in patients with acute myocardial infarction (AMI) without heart failure (HF) or left ventricular systolic dysfunction (LVSD).

      Patients and Methods

      We enrolled patients with AMI without HF or LVSD between June 1, 2003, and February 28, 2015, from Seoul National University Hospital Acute Myocardial Infarction Registry. Patients were categorized according to discharge heart rate recorded on electrocardiographs and β-blocker use. Low heart rate was defined as less than 75 beats/min. The primary end point was 5-year all-cause mortality according to discharge heart rate and β-blocker use.

      Results

      Of 2271 patients, 1696 (74.7%) received β-blockers and 1427 (62.8%) had low heart rates. At 5 years after discharge, 205 patients died. Overall, patients with low heart rates (P<.001) and those with β-blocker treatment had lower mortality (P<.001). After adjustment for covariates, β-blocker use was associated with 48% reduced risk for 5-year mortality in patients with high heart rates (hazard ratio, 0.52; 95% CI, 0.35-0.76), but not in those with low heart rates (P=.97). In an inverse-probability treatment-weighted cohort, β-blocker use was also associated with improved mortality in those with a high heart rate. Findings were similar for 5-year cardiovascular mortality.

      Conclusion

      Among survivors with AMI without HF or LVSD, β-blocker use was associated with reduced 5-year all-cause mortality in patients who have high heart rates, but not in those with low heart rates.

      Abbreviations and Acronyms:

      AMI (acute myocardial infarction), ECG (electrocardiogram), HF (heart failure), HR (hazard ratio), IPTW (inverse-probability treatment-weighted), IRB (Institutional Review Board), LVSD (left ventricular systolic dysfunction), LVEF (left ventricle ejection fraction), STEMI (ST-elevation myocardial infarction)
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Mayo Clinic Proceedings
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

      1. A randomized trial of propranolol in patients with acute myocardial infarction. I. Mortality results.
        JAMA. 1982; 247: 1707-1714
        • Kontos M.C.
        • Diercks D.B.
        • Ho P.M.
        • Wang T.Y.
        • Chen A.Y.
        • Roe M.T.
        Treatment and outcomes in patients with myocardial infarction treated with acute beta-blocker therapy: results from the American College of Cardiology's NCDR((R)).
        Am Heart J. 2011; 161: 864-870
        • Olsson G.
        • Rehnqvist N.
        Evaluation of antiarrhythmic effect of metoprolol treatment after acute myocardial infarction: relationship between treatment responses and survival during a 3-year follow-up.
        Eur Heart J. 1986; 7: 312-319
      2. Randomised trial of intravenous atenolol among 16 027 cases of suspected acute myocardial infarction: ISIS-1. First International Study of Infarct Survival Collaborative Group.
        Lancet. 1986; 2: 57-66
        • Freemantle N.
        • Cleland J.
        • Young P.
        • Mason J.
        • Harrison J.
        beta Blockade after myocardial infarction: systematic review and meta regression analysis.
        BMJ. 1999; 318: 1730-1737
        • Ozasa N.
        • Kimura T.
        • Morimoto T.
        • et al.
        • j-Cypher Registry Investigators
        Lack of effect of oral beta-blocker therapy at discharge on long-term clinical outcomes of ST-segment elevation acute myocardial infarction after primary percutaneous coronary intervention.
        Am J Cardiol. 2010; 106: 1225-1233
        • Puymirat E.
        • Riant E.
        • Aissaoui N.
        • et al.
        β blockers and mortality after myocardial infarction in patients without heart failure: multicentre prospective cohort study [Erratum in β blockers and mortality after myocardial infarction in patients without heart failure: multicentre prospective cohort study. BMJ. 2016].
        BMJ. 2016; 354: i4801
        • O'Gara P.T.
        • Kushner F.G.
        • Ascheim D.D.
        • et al.
        • CF/AHA Task Force
        2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines.
        Circulation. 2013; 127: 529-555
        • Roffi M.
        • Patrono C.
        • Collet J.P.
        • et al.
        • ESC Scientific Document Group
        2015 ESC guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: Task Force for the Management of Acute Coronary Syndromes in Patients Presenting without Persistent ST-Segment Elevation of the European Society of Cardiology (ESC).
        Eur Heart J. 2016; 37: 267-315
        • Dondo T.B.
        • Hall M.
        • West R.M.
        • et al.
        beta-Blockers and mortality after acute myocardial infarction in patients without heart failure or ventricular dysfunction.
        J Am Coll Cardiol. 2017; 69: 2710-2720
        • Kjekshus J.K.
        Importance of heart rate in determining beta-blocker efficacy in acute and long-term acute myocardial infarction intervention trials.
        Am J Cardiol. 1986; 57: 43F-49F
        • Fox K.
        • Ford I.
        • Steg P.G.
        • et al.
        • BEAUTIFUL investigators
        Heart rate as a prognostic risk factor in patients with coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a subgroup analysis of a randomised controlled trial.
        Lancet. 2008; 372: 817-821
        • Park J.J.
        • Kim S.H.
        • Kang S.H.
        • et al.
        Effect of beta-blockers beyond 3 years after acute myocardial infarction.
        J Am Heart Assoc. 2018; 7
        • Fox K.
        • Ford I.
        • Steg P.G.
        • et al.
        • BEAUTIFUL investigators
        Relationship between ivabradine treatment and cardiovascular outcomes in patients with stable coronary artery disease and left ventricular systolic dysfunction with limiting angina: a subgroup analysis of the randomized, controlled BEAUTIFUL trial.
        Eur Heart J. 2009; 30: 2337-2345
        • Hjalmarson A.
        • Elmfeldt D.
        • Herlitz J.
        • et al.
        Effect on mortality of metoprolol in acute myocardial infarction. A double-blind randomised trial.
        Lancet. 1981; 2: 823-827
        • Norwegian Multicenter Study Group
        Timolol-induced reduction in mortality and reinfarction in patients surviving acute myocardial infarction.
        N Engl J Med. 1981; 304: 801-807
        • Chen Z.M.
        • Pan H.C.
        • Chen Y.P.
        • et al.
        • COMMIT (ClOpidogrel and Metoprolol in Myocardial Infarction Trial) collaborative group
        Early intravenous then oral metoprolol in 45,852 patients with acute myocardial infarction: randomised placebo-controlled trial.
        Lancet. 2005; 366: 1622-1632
        • Huang B.T.
        • Huang F.Y.
        • Zuo Z.L.
        • et al.
        Meta-analysis of relation between oral beta-blocker therapy and outcomes in patients with acute myocardial infarction who underwent percutaneous coronary intervention.
        Am J Cardiol. 2015; 115: 1529-1538
        • Smith Jr., S.C.
        • Benjamin E.J.
        • Bonow R.O.
        • et al.
        AHA/ACCF secondary prevention and risk reduction therapy for patients with coronary and other atherosclerotic vascular disease: 2011 update: a guideline from the American Heart Association and American College of Cardiology Foundation endorsed by the World Heart Federation and the Preventive Cardiovascular Nurses Association.
        J Am Coll Cardiol. 2011; 58: 2432-2446
        • Mulder P.
        • Barbier S.
        • Chagraoui A.
        • et al.
        Long-term heart rate reduction induced by the selective I(f) current inhibitor ivabradine improves left ventricular function and intrinsic myocardial structure in congestive heart failure.
        Circulation. 2004; 109: 1674-1679
        • Colin P.
        • Ghaleh B.
        • Monnet X.
        • Hittinger L.
        • Berdeaux A.
        Effect of graded heart rate reduction with ivabradine on myocardial oxygen consumption and diastolic time in exercising dogs.
        J Pharmacol Exp Ther. 2004; 308: 236-240
        • Reil J.C.
        • Reil G.H.
        • Bohm M.
        Heart rate reduction by I(f)-channel inhibition and its potential role in heart failure with reduced and preserved ejection fraction.
        Trends Cardiovasc Med. 2009; 19: 152-157
        • Monfredi O.
        • Boyett M.R.
        Sick sinus syndrome and atrial fibrillation in older persons - a view from the sinoatrial nodal myocyte.
        J Mol Cell Cardiol. 2015; 83: 88-100
        • Cleland J.G.F.
        • Bunting K.V.
        • Flather M.D.
        • et al.
        • Beta-Blockers in Heart Failure Collaborative Group
        Beta-blockers for heart failure with reduced, mid-range, and preserved ejection fraction: an individual patient-level analysis of double-blind randomized trials.
        Eur Heart J. 2018; 39: 26-35
        • Bangalore S.
        • Sawhney S.
        • Messerli F.H.
        Relation of beta-blocker-induced heart rate lowering and cardioprotection in hypertension.
        J Am Coll Cardiol. 2008; 52: 1482-1489
        • Messerli F.H.
        • Rimoldi S.F.
        • Bangalore S.
        • Bavishi C.
        • Laurent S.
        When an increase in central systolic pressure overrides the benefits of heart rate lowering.
        J Am Coll Cardiol. 2016; 68: 754-762
        • Stukel T.A.
        • Fisher E.S.
        • Wennberg D.E.
        • Alter D.A.
        • Gottlieb D.J.
        • Vermeulen M.J.
        Analysis of observational studies in the presence of treatment selection bias: effects of invasive cardiac management on AMI survival using propensity score and instrumental variable methods.
        JAMA. 2007; 297: 278-285